# US 2013/0158112 A1 · Compositions and methods for inhibiting beta amyloid secretion

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0158112 A1
- Document ID: US20130158112A1
- Status: Published application
- Kind: A1
- Application number: 13/527,844
- Filed: 2012-06-20
- Published: 2013-06-20
- Earliest claimed: 2011-06-20
- Inventors: Jonathan D. Smith; Enakshi Chakrabarti; Subrata Ghosh; Marti Sayre; Gregory Tochtrop
- Web page: https://patentgrep.com/patent/US20130158112A1

## CPC

- C07C 323/56: the carbon skeleton containing six-membered aromatic rings
- C07C 233/69: of an acyclic saturated carbon skeleton
- C07C 317/28: with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C 323/42: Y being a carbon atom of a six-membered aromatic ring
- C07C 323/45: having at least one of the nitrogen atoms doubly-bound to the carbon skeleton
- C07C 323/60: with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
- C07C 2601/02: with a three-membered ring
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

A pharmaceutical composition for inhibiting amyloid beta peptide in a subject includes a compound having the formula (I): where M is selected from a substituted or unsubstituted alkyl, halo, alkoxy, aryl, cyclic, or heterocyclic group; p is an integer from 0-3; X1 is a 3-9 atoms in length linker connecting A and B; B is selected from a substituted or unsubstituted aryl, alkoxy or amine group; and a pharmaceutically acceptable salt thereof; and a pharmaceutical carrier.

## Claims

### Claim 1

A pharmaceutical composition for inhibiting amyloid β peptide secretion in a subject, the composition comprising a compound having the formula (I):
where M is selected from a substituted or unsubstituted alkyl, halo, alkoxy, aryl, cyclic, or heterocyclic group;
p is an integer from 0-3;
X1 is a 3-9 atoms in length linker connecting A and B;
B is selected from a substituted or unsubstituted aryl, alkoxy or amine group; and
a pharmaceutically acceptable salt thereof; and a pharmaceutical carrier.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, the compound comprising the formula (II):
where R1 and R2 are individually selected from a substituted or unsubstituted, aryl, cyclic, or heterocyclic group;
X1 is a 6-7 atoms in length linker connecting A and B;
Z is a substituted or unsubstituted alkyl, halo, alkoxy, or amine group;
q is an integer from 0-3; and pharmaceutically acceptable salts thereof.

### Claim 3 (depends on 2)

The pharmaceutical composition of claim 2, X1 comprising the following structure:
where X2 is selected from CH2 and CO;
X3 is selected from NH, CH2 and CO;
X4 is selected from NH and CH2;
X5 is CH2;
X6 is selected from SH2, SHO, SO2 and CH2;
X7 is selected from SH2, SHO, SO2 and CH2; and
X8 is selected from nothing and CH2.

### Claim 4 (depends on 2)

The pharmaceutical composition of claim 2, where R1 and R2 are independently selected from H, Cl, CH3, OH, NO2, F, Br, CF3, or an alkoxy group.

### Claim 5 (depends on 2)

The pharmaceutical composition of claim 2, where Z is selected from Cl, alkoxy, OH, CN, C(NH2)NOH, NO2, NH2, CO2Et, COOH, CONH, F, CH2, CHO, CF3, BR, I, CONHC3H5, NHCOC3H5 and OCH2CH2OCH2CH2OH.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, the compound is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.

### Claim 7 (depends on 1)

The pharmaceutical composition of claim 1, the compound comprising:
and pharmaceutically acceptable salts thereof.

### Claim 8 (depends on 1)

The pharmaceutical composition of claim 1, the compound is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.

### Claim 9

A method for inhibiting amyloid β peptide secretion in a subject, the method comprising:
administering to the subject a therapeutically effective amount of a pharmaceutical composition, the pharmaceutical composition including a compound having the formula (I):
where M is selected from a substituted or unsubstituted alkyl, halo, alkoxy, aryl, cyclic, or heterocyclic group;
p is an integer from 0-3;
X1 is a 3-9 atoms in length linker connecting A and B;
B is selected from a substituted or unsubstituted aryl, alkoxy or amine group; and
a pharmaceutically acceptable salt thereof; and a pharmaceutical carrier.

### Claim 10 (depends on 9)

The method of claim 9, the compound comprising the formula (II):
where R1 and R2 are individually selected from a substituted or unsubstituted, aryl, cyclic, or heterocyclic group;
X1 is a 6-7 atoms in length linker connecting A and B;
Z is a substituted or unsubstituted alkyl, halo, alkoxy, or amine group;
q is an integer from 0-3; and pharmaceutically acceptable salts thereof.

### Claim 11 (depends on 10)

The method of claim 10, X1 comprising the following structure:
where X2 is selected from CH2 and CO;
X3 is selected from NH, CH2 and CO;
X4 is selected from NH and CH2;
X5 is CH2;
X6 is selected from SH2, SHO, SO2 and CH2;
X7 is selected from SH2, SHO, SO2 and CH2; and
X8 is selected from nothing and CH2.

### Claim 12 (depends on 10)

The method of claim 10 where R3 and R4 are independently selected from H, Cl, CH3, OH, NO2, F, Br, CF3 and an alkoxy group.

### Claim 13 (depends on 10)

The method of claim 10, where Z is selected from Cl, alkoxy, OH, CN, C(NH2)NOH, NO2, NH2, CO2Et, COOH, CONH, F, CH2, CHO, CF3, BR, I, CONHC3H5, NHCOC3H5 and OCH2CH2OCH2CH2OH.

### Claim 14 (depends on 9)

The method of claim 9, the compound is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.

### Claim 15 (depends on 9)

The method of claim 9, the compound is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.

### Claim 16

A method for treating a neurological or neurodegenerative disorder in a subject, the method comprising:
administering to the subject a therapeutically effective amount of a pharmaceutical composition, the pharmaceutical composition including a compound having the formula (I):
where M is selected from a substituted or unsubstituted alkyl, halo, alkoxy, aryl, cyclic, or heterocyclic group;
p is an integer from 0-3;
X1 is a 3-9 atoms in length linker connecting A and B;
B is selected from a substituted or unsubstituted aryl, alkoxy or amine group; and
a pharmaceutically acceptable salt thereof; and a pharmaceutical carrier.

### Claim 17 (depends on 16)

The method of claim 16, the compound comprising the formula (II):
where R1 and R2 are individually selected from a substituted or unsubstituted, aryl, cyclic, or heterocyclic group;
X1 is a 6-7 atoms in length linker connecting A and B;
Z is a substituted or unsubstituted alkyl, halo, alkoxy, or amine group;
q is an integer from 0-3; and pharmaceutically acceptable salts thereof.

### Claim 18 (depends on 17)

The method of claim 17, X1 comprising the following structure:
where X2 is selected from CH2 and CO;
X3 is selected from NH, CH2 and CO;
X4 is selected from NH and CH2;
X5 is CH2;
X6 is selected from SH2, SHO, SO2 and CH2;
X7 is selected from SH2, SHO, SO2 and CH2; and
X8 is selected from nothing and CH2.

### Claim 19 (depends on 17)

The method of claim 17 where R3 and R4 are independently selected from H, Cl, CH3, OH, NO2, F, Br, CF3 and an alkoxy group.

### Claim 20 (depends on 17)

The method of claim 17, where Z is selected from Cl, alkoxy, OH, CN, C(NH2)NOH, NO2, NH2, CO2Et, COOH, CONH, F, CH2, CHO, CF3, BR, I, CONHC3H5, NHCOC3H5 and OCH2CH2OCH2CH2OH.

### Claim 21 (depends on 16)

The method of claim 16, the compound is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.

### Claim 22 (depends on 16)

The method of claim 16, the compound is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.

### Claim 23 (depends on 16)

The method of claim 16, the pharmaceutical composition promoting neuronal survival in the subject.
